Volume 19, Issue 4, Pages (April 2018)

Slides:



Advertisements
Similar presentations
Volume 14, Issue 4, Pages (April 2013)
Advertisements

Volume 18, Issue 6, Pages (June 2017)
Volume 376, Issue 9747, Pages (October 2010)
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised,
Volume 18, Issue 7, Pages (July 2017)
Volume 11, Issue 4, Pages (April 2012)
Volume 15, Issue 6, Pages (May 2014)
Demographic and practice factors predicting repeated non-attendance in primary care: a national retrospective cohort analysis  David A Ellis, PhD, Ross.
Volume 14, Issue 4, Pages (April 2013)
Volume 377, Issue 9783, Pages (June 2011)
Transmission of Staphylococcus aureus between health-care workers, the environment, and patients in an intensive care unit: a longitudinal cohort study.
Volume 373, Issue 9666, Pages (March 2009)
Volume 389, Issue 10076, Pages (April 2017)
Volume 14, Issue 3, Pages (March 2013)
Volume 388, Issue 10052, Pages (October 2016)
Volume 15, Issue 2, Pages (February 2014)
Volume 18, Issue 7, Pages (July 2017)
Volume 15, Issue 4, Pages (April 2014)
Volume 18, Issue 6, Pages (June 2017)
Volume 15, Issue 4, Pages (April 2014)
Volume 389, Issue 10071, Pages (February 2017)
Volume 373, Issue 9663, Pages (February 2009)
Volume 391, Issue 10121, Pages (February 2018)
Volume 15, Issue 4, Pages (April 2014)
Volume 17, Issue 9, Pages (September 2016)
Volume 14, Issue 8, Pages (July 2013)
Volume 18, Issue 7, Pages (July 2017)
Volume 14, Issue 8, Pages (July 2013)
Volume 12, Issue 7, Pages (July 2011)
Volume 15, Issue 6, Pages (May 2014)
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised,
Volume 18, Issue 3, Pages (March 2017)
Volume 15, Issue 1, Pages (January 2014)
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.
Volume 387, Issue 10023, Pages (March 2016)
Volume 389, Issue 10073, Pages (March 2017)
Volume 14, Issue 6, Pages (May 2013)
Volume 20, Issue 1, Pages (January 2019)
Volume 14, Issue 11, Pages (October 2013)
Volume 388, Issue 10047, Pages (August 2016)
Volume 373, Issue 9666, Pages (March 2009)
Volume 18, Issue 3, Pages (March 2017)
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,
Volume 15, Issue 8, Pages (July 2014)
Volume 371, Issue 9625, Pages (May 2008)
Volume 373, Issue 9676, Pages (May 2009)
Volume 18, Issue 8, Pages (August 2017)
Volume 16, Issue 15, Pages (November 2015)
Volume 388, Issue 10055, Pages (October 2016)
Volume 15, Issue 6, Pages (May 2014)
Volume 392, Issue 10162, Pages (December 2018)
Volume 14, Issue 6, Pages (May 2013)
Volume 13, Issue 11, Pages (November 2012)
Volume 16, Issue 15, Pages (November 2015)
Volume 16, Issue 8, Pages (August 2015)
Volume 14, Issue 8, Pages (July 2013)
Volume 19, Issue 10, Pages (October 2018)
Volume 15, Issue 6, Pages (May 2014)
Volume 15, Issue 8, Pages (July 2014)
Volume 11, Issue 1, Pages (January 2010)
Volume 18, Issue 10, Pages (October 2017)
Volume 376, Issue 9747, Pages (October 2010)
Volume 13, Issue 5, Pages (May 2012)
Volume 372, Issue 9632, Pages (July 2008)
Volume 5, Issue 1, Pages (January 2018)
Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.
Volume 20, Issue 5, Pages (May 2019)
Volume 14, Issue 7, Pages (June 2013)
Volume 20, Issue 7, Pages (July 2019)
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international,
Presentation transcript:

Volume 19, Issue 4, Pages 562-578 (April 2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial  Timothy J Iveson, MD, Prof Rachel S Kerr, FRCP, Mark P Saunders, FRCR, Prof Jim Cassidy, MD, Niels Henrik Hollander, MD, Josep Tabernero, MD, Andrew Haydon, MBBS, Prof Bengt Glimelius, MD, Andrea Harkin, BA, Karen Allan, BSc, John McQueen, BSc, Claire Scudder, MSc, Kathleen Anne Boyd, PhD, Prof Andrew Briggs, DPhil, Ashita Waterston, PhD, Louise Medley, FRCP, Charles Wilson, FRCR, Richard Ellis, FRCR, Sharadah Essapen, MD, Amandeep S Dhadda, MBChB, Mark Harrison, PhD, Stephen Falk, MD, Sherif Raouf, FRCR, Charlotte Rees, FRCP, Rene K Olesen, MD, David Propper, MD, Prof John Bridgewater, MD, Ashraf Azzabi, MD, David Farrugia, PhD, Andrew Webb, FRCP, Prof David Cunningham, MD, Tamas Hickish, MD, Andrew Weaver, MD, Simon Gollins, DPhil, Harpreet S Wasan, FRCP, James Paul, BSc [Hons]  The Lancet Oncology  Volume 19, Issue 4, Pages 562-578 (April 2018) DOI: 10.1016/S1470-2045(18)30093-7 Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 1 Trial profile ITT=intention to treat. CTCAE=Common Terminology Criteria for Adverse Events. *Based on retrospective review. †Patients could have more than one reason. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 2 Disease-free survival (A) and overall survival (B) by study group HR=hazard ratio. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 3 Disease-free survival and heterogeneity in subgroups by minimisation variables Categories are listed as recorded at randomisation; ten patients in the 3 month group and 15 patients in the 6 month group could not be allocated to high risk stage II or stage III based on T/N data recorded at randomisation. *These estimates differ slightly because the underlying multivariable Cox model on which they are based includes parameters for other minimisation variables, as well as those factors relating to stage; the increased flexibility in the expanded stage model allows the influence of these parameters on the high risk stage II estimates to modify. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 4 Disease-free survival by study group and selected adjuvant regimen HR=hazard ratio. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 5 Treatment delivery by selected adjuvant regimen Box and whisker plots indicate median and IQR (boxes) and range (whiskers). Dots represent outliers. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 6 Disease-free survival by study group and stage III risk group HR=hazard ratio. The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions

Figure 7 Peripheral neuropathy by study group Patients reported peripheral neuropathy with the GOG Ntx4 questionnaire. Although results were available beyond year 6, they have been omitted because of small numbers and resultant wide confidence intervals. Error bars show 95% CIs. *The low completion rates at these timepoints reflect the fact that, initially, neurotoxicity data were only collected up to 12 months and there was a delay before an amendment extended the collection to the whole study period. †Low return rate because patients were assessed at the start of last cycle rather than 6 months (which corresponds to end of cycle). The Lancet Oncology 2018 19, 562-578DOI: (10.1016/S1470-2045(18)30093-7) Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Terms and Conditions